You are here: Industry Insights > TGF-β

News List

Transcenta Announces First Patient Dosed in Global Phase I Clinical Trial of PD-L1/TGF-β Bi-functional Antibody TST005 prnasia
July 15, 2021
Transcenta Holding Limited announces that the first US patient has been dosed in the global Phase I clinical trial of PD-L1/TGF-β bi-functional antibody TST005.
Transcenta Received IND Clearance from US FDA for Initiating Phase I Clinical Trial for its Bi-functional Anti-PD-L1/TGF-β Antibody TST005 prnasia
April 21, 2021
Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of ...
NMPA Accepts Application for Clinical Trial of Bifunctional Fusion Protein contractpharma
March 10, 2021
JS201, developed by Junshi Biosciences, can simultaneously target PD-1 and TGF-β.
CMAB Biopharma Congratulates Partner Junshi Biosciences on NMPA Acceptance of Application for a Clinical Trial of its PD-1/TGF-β Bifunctional Fusion Protein prnasia
March 08, 2021
Recently, CMAB Biopharma (Suzhou) Inc's partner Shanghai Junshi Biosciences Co., Ltd., announced that a clinical trial application for its PD-1/TGF-β bifunctional fusion protein JS201 injection (JS201) has been accepted by National Medical Products ...
Windlas Biotech, Mateon Therapeutics launch drug-device plus lung therapy platform expresspharma
March 08, 2021
Interim data from clinical trials show PulmoHeal’s efficacy in improving recovery of mild and moderate Covid-19 patients.